Arbutus Biopharma Corporation vs Absci Corporation
ABUS and ABSI are evenly matched across key metrics.
🏆 Tale of the Tape
Green = winner in each category. Higher is better except P/E (lower = cheaper).
Fundamentals
| Metric | ABUS | ABSI |
|---|---|---|
| Market Cap | — | $1.1B |
| P/E Ratio | — | — |
| Forward P/E | — | -10.6x |
| P/B | — | 6.10x |
| Dividend Yield | — | — |
| Beta | — | 2.38 |
Quantitative Metrics
| Metric | ABUS | ABSI |
|---|---|---|
| DCF Fair Value | — | — |
| DCF Upside | — | — |
| Piotroski F | 4/9 | 2/9 |
| Altman Z | — | 5.11 |
| Beneish M | — | — |
| FCF Yield | — | -21.57% |
| Net Debt/EBITDA | — | — |
| ROIC | -29.8% | -46.9% |
| WACC | — | — |
| ROIC – WACC | — | — |
| Gross Margin | — | — |
| Net Margin | -237.9% | -4113.7% |
| Rev Growth YoY | 128.2% | -38.2% |
| Sharpe (1Y) | — | 0.56 |
| Max Drawdown 3Y | — | -66.1% |
| FCF Payout Ratio | — | — |
ABUS Price
ABSI Price
ETF Exposure
More Comparisons
Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.
ABUS vs ABSI: Head-to-Head Analysis
Arbutus Biopharma Corporation (ABUS) and Absci Corporation (ABSI) represent two companies in the Healthcare sector. Our quantitative Tale of the Tape shows these companies are evenly matched across profitability, valuation, and risk metrics.
In terms of capital efficiency, ABUS generates a return on invested capital (ROIC) of -29.8% compared to ABSI's -46.9%. This suggests ABUS is more effective at deploying capital to generate shareholder returns.
ABUS appears in 2 ETFs tracked by SecuritiesDB, while ABSI appears in 2 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.
Frequently Asked Questions
Which stock is the better investment, ABUS or ABSI?
Our quantitative analysis compares ABUS and ABSI across nine fundamental dimensions. ABUS and ABSI are evenly matched across key metrics. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.
Are ABUS and ABSI correlated?
Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.
How is the Tale of the Tape scored?
The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.